Tumor Necrosis Factor Inhibitor Drugs Market Report 2025

The tumor necrosis factor inhibitor drugs market size has grown marginally in recent years. It will grow from $42.22 billion in 2024 to $42.9 billion in 2025 at a compound annual growth rate (CAGR) of 1.6%. The growth in the historic period can be attributed to clinical efficacy, FDA approvals, increased disease prevalence, clinical trials and research, physician adoption and recommendations, patient demand and satisfaction.

The tumor necrosis factor inhibitor drugs market size is expected to see steady growth in the next few years. It will grow to $48.24 billion in 2029 at a compound annual growth rate (CAGR) of 3%. The growth in the forecast period can be attributed to emerging markets growth, regulatory changes and approvals, personalized medicine approaches, healthcare awareness and access, biological therapies advancements. Major trends in the forecast period include patient-centric solutions, real-world evidence and data, focus on safety and side effects, advanced drug delivery systems, expanded clinical applications.

The rising prevalence of autoimmune illnesses is poised to drive the growth of the tumor necrosis factor inhibitor drugs market. Autoimmune disorders, characterized by the immune system mistakenly attacking healthy human tissue, often result in inflammation, pain, and swelling. Tumor necrosis factor inhibitor drugs play a crucial role in mitigating these effects by blocking inflammation, providing relief from associated symptoms, and stabilizing the immune system. As of June 2022, the Autoimmune Association reported that 4.7 million men in the US were affected by autoimmune diseases, constituting 20% of all autoimmune disease patients. Additionally, a total of 31 million individuals in the US were reported to be suffering from 80-150 unique autoimmune diseases in 2022, with expectations of further increases in the future. Consequently, the escalating prevalence of autoimmune disorders serves as a driving force for the growth of the tumor necrosis factor inhibitor drugs market.

Rising healthcare expenditures are expected to drive the growth of the tumor necrosis factor inhibitor drug market. Healthcare expenditures refer to the total amount spent on healthcare services, products, and activities over a specific period, which can be measured on an individual, community, national, or global scale. Increased healthcare spending is often linked to better access to advanced and costly treatments, including biologic drugs such as TNF inhibitors. For example, in January 2024, the National Institutes of Health, a US-based government agency, reported that healthcare spending in the US increased by 4.1% in 2022, reaching $4.5 trillion. This growth rate was faster than the 3.2% increase noted in 2021. Therefore, the rising healthcare expenditure will contribute to the growth of the tumor necrosis factor inhibitor drug market.

Product innovations are a significant trend gaining traction in the tumor necrosis factor inhibitor drugs market. Leading companies in this market are concentrating on developing innovative products to enhance their competitive position. For example, in May 2024, Teva Pharmaceuticals, a US-based pharmaceutical firm, collaborated with Alvotech, a biotechnology company based in Luxembourg, to announce the launch of SIMLANDI (adalimumab-ryvk) injection in the U.S. This product serves as an interchangeable biosimilar to Humira for treating various conditions, including adult rheumatoid arthritis, juvenile idiopathic arthritis, adult psoriatic arthritis, adult ankylosing spondylitis, Crohn’s disease, adult ulcerative colitis, adult plaque psoriasis, adult hidradenitis suppurativa, and adult uveitis.

Major players in the tumor necrosis factor inhibitor drug market are strategically embracing a partnership approach to create a new oral medicine for irritable bowel disease (IBD). Strategic partnerships involve companies leveraging each other's strengths and resources to achieve mutual benefits. In July 2022, SGS S.A., a Switzerland-based inspection, verification, testing, and certification service, announced a collaboration with CPI, Pharmidex, and Intract Pharma. The partnership aims to repackage the biologic medication infliximab, a tumor necrosis factor (TNF) inhibitor drug used for various inflammatory conditions, including IBD, into an oral capsule. This innovative oral delivery method for infliximab seeks to provide IBD patients with a more focused, convenient, and safer treatment option by withstanding the harsh conditions of the stomach. Intract Pharma Limited, Pharmidex Pharmaceutical Services Ltd., and CPI are all UK-based entities contributing their expertise to this collaborative effort.

In April 2022, Samsung Biologics, a prominent South Korea-based biotechnology company, successfully acquired Samsung Bioepis Co. Ltd. for a significant sum of $2.3 billion. This strategic acquisition is poised to enhance Samsung Biologics' capabilities in biosimilar development and position the company for improved performance in the realm of novel drug development. The acquisition is expected to provide Samsung Bioepis with greater autonomy and agility in its business operations. Samsung Bioepis Co. Ltd., also based in South Korea, is a leading biopharmaceutical company specializing in the production of tumor necrosis factor inhibitor drugs. The acquisition marks a significant move for Samsung Biologics to bolster its position in the biopharmaceutical industry and further its contributions to the development of vital medications in the tumor necrosis factor inhibitor drugs market.

Major companies operating in the tumor necrosis factor inhibitor drugs market include AbbVie Inc., Amgen Inc., Johnson & Johnson Services Inc., UCB S.A., Novartis International AG, Pfizer Inc., Samsung Bioepis Co. Ltd., Sanofi SA, Merck & Co. Inc., Boehringer Ingelheim Pharmaceuticals, Lupin Ltd., F. Hoffmann-La Roche AG, Cadila Healthcare Ltd., Aryogen Biopharma, Casi Pharmaceuticals, Celltrion Inc., Bristol-Myers Squibb, Dexa Medica, Epirus Biopharmaceuticals, Glaxosmithkline plc, Hanall Biopharma, Intas Pharmaceuticals, Leo Pharma AS, Biogen Inc.

North America was the largest region in the tumor necrosis factor inhibitor drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the tumor necrosis factor (TNF) inhibitors drugs market report during the forecast period. The regions covered in the tumor necrosis factor inhibitor drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the tumor necrosis factor inhibitor drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tumor necrosis factor (TNF) inhibitor drugs are medications designed to alleviate inflammation. These drugs work by suppressing the inflammatory response triggered by TNF cytokines, thereby treating various inflammatory and autoimmune conditions.

Key types of TNF inhibitor drugs available in the market include Humira, Enbrel, Remicade, Simponi/Simponi Aria, Cimzia, and biosimilars. Humira, for instance, is a TNF blocker that diminishes the effects of substances in the body responsible for inflammation. These medications are administered via subcutaneous or intravenous injection routes and are distributed through hospital pharmacies, retail pharmacies, and online pharmacies. They are prescribed for conditions such as rheumatoid arthritis, psoriasis, psoriatic arthritis, Crohn’s disease, ulcerative colitis, ankylosing spondylitis, juvenile idiopathic arthritis, hidradenitis suppurativa, among others, to mitigate their symptoms and manage the underlying inflammation.

The tumor necrosis factor (TNF) inhibitor drugs market research report is one of a series of new reports that provides tumor necrosis factor (TNF) inhibitor drugs market statistics, including global market size, regional shares, competitors with a tumor necrosis factor (TNF) inhibitor drugs market share, detailed tumor necrosis factor (TNF) inhibitor drugs market segments, market trends and opportunities, and any further data you may need to thrive in the tumor necrosis factor (TNF) inhibitor drugs industry. This tumor necrosis factor (TNF) inhibitor drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The tumor necrosis factor (TNF) inhibitors drugs market consists of sales of enbrel, ereizi, inflectra, and renflexis. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.